10-K: Stryker Reports Strong 2025 Growth Amid Strategic Acquisitions

Sentiment:

Annual Report 11 February 2026 11:43 AM

Stryker Corporation achieved robust net sales and adjusted earnings growth in 2025, driven by strategic acquisitions and innovative product launches across its MedSurg, Neurotechnology, and Orthopaedics segments.

Delay expectedThe European Union Medical Device Regulation (MDR) had an original effective date of May 2022, but extended transition timelines were published in 2023, ranging from May 2026 through December 2028, indicating a delay in full compliance for manufacturers.

Capital raiseIssued $500 million of 4.550% senior unsecured notes due February 10, 2027, in February 2025.Issued $700 million of 4.700% senior unsecured notes due February 10, 2028, in February 2025.Issued $800 million of 4.850% senior unsecured notes due February 10, 2030, in February 2025.Issued $1,000 million of 5.200% senior unsecured notes due February 10, 2035, in February 2025.Entered into a new revolving credit agreement in February 2025, increasing the aggregate principal amount by $750 million to $3,000 million and extending the maturity date to February 25, 2030.

Better than expectedNet sales increased by 11.2% to $25,116 million, exceeding prior year growth.Adjusted net earnings grew by 11.8% to $5,267 million, demonstrating strong underlying business performance.Adjusted diluted EPS increased by 11.8% to $13.63, indicating improved profitability on an adjusted basis.Cash provided by operating activities increased to $5,044 million, reflecting strong cash generation.

Summary

Net sales for 2025 increased by 11.2% to $25,116 million, with constant currency growth of 10.7% and organic sales growth of 9.9% (excluding acquisitions and divestitures).
Adjusted net earnings grew by 11.8% to $5,267 million, resulting in adjusted diluted EPS of $13.63, an 11.8% increase.
The company invested $4,960 million in acquisitions during 2025, including Inari Medical, Inc., Guard Medical Inc., and Advanced Medical Balloons (AMB).
Key product launches included Steri-Shield 8 (OR PPE), Connected OR IP BRAVoE (endoscopy), LIFEPAK 35 monitor/defibrillator, Vocera Sync Badge (communication), Broadway System (stroke solution), Surpass Elite Flow Diverting Stent, and OptaBlate BVN (nerve ablation).
The Mako SmartRobotics platform expanded globally to over 45 countries, with more than 2 million robotic procedures performed to date, and the Mako 4 platform was introduced with new applications like Total Hip Advanced Primary and Revision, and Mako Shoulder.
The Spinal Implants business was divested in April 2025 to Viscogliosi Brothers, LLC, following a goodwill impairment charge of $456 million and an estimated loss of $362 million in 2024 related to this business.
Interest expense increased significantly by 48.4% to $607 million in 2025 due to new debt issuances.
The effective tax rate rose to 28.1% in 2025 from 14.3% in 2024, primarily due to the tax effect of intellectual property transfers between tax jurisdictions.
Cash provided by operating activities increased to $5,044 million in 2025, up from $4,242 million in 2024.
Stryker issued $3,000 million in new senior unsecured notes in February 2025 and repaid $1,400 million in maturing notes during the year.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as largely positive, reflecting strong financial growth, strategic acquisitions, and significant product innovation. While increased interest expense and a higher effective tax rate present challenges, the underlying operational performance and strategic direction are robust.

Positives

Achieved strong net sales growth of 11.2% and constant currency growth of 10.7% in 2025.
Reported robust adjusted net earnings growth of 11.8% and adjusted diluted EPS growth of 11.8% in 2025.
Successfully integrated strategic acquisitions like Inari Medical, Inc., Guard Medical Inc., and Advanced Medical Balloons, expanding product portfolios in key segments.
Launched several innovative products and platforms, including Steri-Shield 8, LIFEPAK 35, Vocera Sync Badge, Broadway System, Surpass Elite Flow Diverting Stent, OptaBlate BVN, and the Mako 4 platform with new robotic applications.
Expanded the global footprint of Mako SmartRobotics to over 45 countries, demonstrating strong market penetration and adoption of advanced surgical technologies.
Increased cash provided by operating activities to $5,044 million, indicating strong operational cash generation.
Maintained strong investment-grade debt ratings, allowing ready access to capital markets at competitive rates.

Negatives

Net earnings growth was 8.5% in 2025, but diluted EPS growth was 8.2%, lower than adjusted figures, indicating significant non-GAAP adjustments.
Reported net earnings and diluted EPS in 2024 declined by 5.4% and 5.9% respectively, compared to 2023.
Interest expense increased substantially by 48.4% in 2025 to $607 million, driven by new debt issuances.
The effective tax rate significantly increased to 28.1% in 2025 from 14.3% in 2024, primarily due to tax effects of intellectual property transfers.
Incurred goodwill impairment charges of $456 million and an estimated loss of $362 million in 2024 related to the Spinal Implants business, which was subsequently divested.

Risks

Supply chain disruptions, raw material shortages, and price increases due to inflation, regulatory changes, litigation, tariffs, or geopolitical tensions could increase operating costs and impact competitive position.
Ongoing pricing pressures from cost containment measures, changes in reimbursement practices, and healthcare industry consolidation could adversely affect product demand and profitability.
Operating in a highly competitive industry requires continuous innovation, and failure to develop new products or integrate emerging technologies (e.g., AI, robotics) could lead to product obsolescence and negatively impact market position.
Inability to maintain adequate working relationships with healthcare professionals due to regulatory restrictions or other reasons could adversely affect product development and sales.
Extensive global operations expose the company to risks from regulatory changes, diminished intellectual property protection, tariffs, trade disputes, political/economic instability, transportation disruptions, and currency fluctuations.
Acquisitions inherently carry risks, including integration challenges, failure to realize anticipated benefits, loss of key personnel, litigation, and antitrust scrutiny.
Material failures or breaches of IT systems, networks, or products, including cyber-attacks, data leakage, unauthorized access, and vulnerabilities in open-source software, could disrupt operations and compromise data security.
Unsuccessful implementation of the new commercial global enterprise resource planning (ERP) system could adversely affect operations and financial results.
Inability to attract, develop, and retain executives and key employees due to labor shortages, increased unionization, or uncompetitive compensation could hinder strategic objectives.
Interruption of manufacturing operations due to natural disasters, equipment breakdown, IT system failures, or regulatory compliance issues could affect product availability and market share.
Inadequate insurance coverage may not fully cover future losses from product liability, intellectual property infringement, environmental, or cybersecurity incidents.
Shifting market demand, particularly for elective medical procedures, and customer staffing shortages could negatively affect sales and profitability.
The use of AI and other emerging technologies introduces risks related to deficient AI-generated content, competitive adoption, regulatory uncertainty, intellectual property, and data protection.
Changes in tax laws, regulations, and judicial rulings, including those related to OECD Pillar 1 and Pillar 2 frameworks, could impact future tax expense.
Ongoing legal proceedings, including product liability claims (e.g., Rejuvenate, ABGII, LFIT V40, Wright legacy hip products) and regulatory matters (e.g., German FCTO audit, EU Product Liability Directive), could result in significant penalties or expenses.
Fluctuations in foreign currency exchange rates can significantly affect financial results, despite hedging strategies.
Future capital requirements may not be met on favorable terms, impacting liquidity and growth, especially with changes in credit ratings or economic conditions.
Evolving corporate responsibility and sustainability expectations, including climate-related matters, could lead to increased costs, regulatory proceedings, or reputational damage.
Physical weather events and environmental regulations could disrupt operations, supply chains, and increase costs.

Future Outlook

Stryker aims to achieve sales growth at the high-end of the medical technology industry and maintain its capital allocation strategy, prioritizing acquisitions, dividends, and share repurchases. The company plans for the full commercial launch of Mako Shoulder in the United States in the first quarter of 2026. Stryker is continuing to evaluate the impact of tax reform in various countries, including the OECD's Pillar 1 and Pillar 2 frameworks, which could affect future tax expense. The company also anticipates continued inflationary pressures and potential impacts from tariffs and geopolitical events.

Management Comments

We are driven to make healthcare better, together with our customers, by offering innovative products and services.
Our core values of integrity, accountability, people, and performance are fundamental to how we execute our mission.
Our success depends on our ability to attract the best talent, and we continue to focus on establishing and maintaining a great workplace.
We have no present intention to engage in a transaction involving a Change of Control, although it is possible that we would decide to do so in the future.
We could, in the future, enter into certain transactions, including acquisitions, refinancings or other recapitalizations, that would not constitute a Change of Control but that could increase the amount of debt outstanding at such time or otherwise affect our capital structure or credit ratings.

Industry Context

StockSavvy.ai notes that Stryker's strong performance in 2025, particularly its double-digit sales and adjusted earnings growth, positions it favorably within the competitive medical technology (MedTech) industry. The company's aggressive acquisition strategy, exemplified by the Inari Medical purchase, aligns with broader industry trends of consolidation and expansion into high-growth, minimally invasive segments. Competitors like Zimmer Biomet, Medtronic, Johnson & Johnson MedTech, and Smith & Nephew are also heavily investing in innovation and robotics, making Stryker's Mako SmartRobotics advancements crucial for maintaining its leadership. The increased interest expense and higher effective tax rate reflect broader macroeconomic and regulatory shifts impacting the entire sector, while the focus on AI-assisted technologies and digital integration mirrors the industry's push towards 'Smart Hospital' solutions.

Comparison to Industry Standards

Stryker's 11.2% net sales growth in 2025 (10.7% in constant currency) is at the high-end of the medical technology industry, demonstrating strong market penetration and demand for its innovative products compared to peers like Medtronic and Johnson & Johnson MedTech.
The expansion of Mako SmartRobotics to over 45 countries and the completion of over 2 million robotic procedures across various joint replacements highlight a leading position in robotic-arm assisted surgery, a key growth area where competitors like Zimmer Biomet also have significant offerings.
The introduction of the Mako 4 platform with advanced hip and shoulder applications demonstrates a commitment to innovation that is critical for maintaining a competitive edge against rivals in the joint replacement and trauma markets.
The acquisition of Inari Medical, Inc. for $4,810 million in 2025, focusing on venous thromboembolism, indicates a strategic move into high-growth, minimally invasive vascular interventions, a segment where companies like Terumo Corporation and Penumbra, Inc. are also active.
The increase in interest expense by 48.4% in 2025 reflects a more aggressive debt financing strategy for acquisitions compared to some peers who might prioritize organic growth or have lower debt leverage.
The significant rise in the effective tax rate to 28.1% in 2025, partly due to intellectual property transfers, suggests a unique tax planning impact that may differentiate its tax burden from global benchmarks, which are also navigating complex international tax reforms like OECD's Pillar 2.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Group President, Orthopaedics	NA	Dylan B. Crotty	2026	Promotion to executive officer role.
Vice President, Chief Digital and Information Officer	NA	Debra King	May 2025	Joined Stryker from Bunge, bringing external expertise.
Vice President, Chief Communications Officer	NA	Kimberly A. Montagnino	2025	Joined Stryker in June 2024, previously held corporate affairs roles at Johnson & Johnson MedTech.
Vice President, Chief Financial Officer	NA	Preston W. Wells	2025	Promotion to executive officer role.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Bylaws/Articles Update	Restated Articles of Incorporation and Amended and Restated Bylaws are in effect, governing corporate structure and shareholder rights.	NA	These documents define the authorized capital stock, voting rights, dividend distribution, and anti-takeover provisions, influencing corporate control and shareholder influence.
Director Liability Limitation	Articles provide that directors are not personally liable to Stryker or its shareholders for acts or omissions to the full extent authorized by the Michigan Business Corporation Act (MBCA).	NA	Reduces personal risk for directors, potentially encouraging board service, but does not limit liability under federal securities laws or affect equitable remedies.
Anti-Takeover Provisions	Provisions in articles and bylaws, including the MBCA's Chapter 7A (Business Combination Act), advance notice requirements for shareholder proposals, and 'blank check' preferred stock, may delay, defer, or prevent a change of control.	NA	These provisions are designed to encourage negotiations with the Board of Directors for unsolicited takeover proposals, potentially limiting shareholder ability to effect rapid changes in control.
Special Shareholder Meetings	Special meetings of shareholders can be called by the Chair, CEO, President, Board of Directors, or upon written request of one or more record holders representing not less than 25% of issued and outstanding common stock.	NA	Provides a mechanism for significant shareholders to call special meetings, offering a degree of shareholder influence on corporate matters.
Cybersecurity Oversight	Cybersecurity risks are overseen by the full Board of Directors and the Audit Committee, with the CISO providing comprehensive updates at least three times a year to the Audit Committee and periodically to the full Board.	NA	Demonstrates a structured approach to managing cybersecurity risks at the highest governance levels, integrating it into strategic objectives and ensuring regular review.
Insider Trading Policies	Corporate Policy 6 (Trading in Securities by Company Personnel) and Insider Trading Guidelines are adopted, governing securities trading by employees and directors.	August 1, 2023 (Guidelines)	Aims to ensure compliance with insider trading laws, prevent misuse of material non-public information, and protect the company and individuals from legal and reputational harm.

Legal Proceedings

Involved in various ongoing legal proceedings, actions, and claims related to product liability, labor, tax, and intellectual property.
Accrual for product liability matters, including Rejuvenate and ABG II Modular-Neck hip stems, LFIT Anatomic CoCr V40 Femoral Heads, and Wright Medical Group N.V. legacy hip products, was $144 million as of December 31, 2025.
The U.S. Department of Justice (DOJ) closed its inquiry into certain business activities in foreign countries related to the Foreign Corrupt Practices Act (FCPA) on April 1, 2025.
The U.S. Securities and Exchange Commission (SEC) closed its FCPA inquiry on December 16, 2025.
Currently responding to inquiries by certain foreign authorities arising in the normal course of business, which are not expected to have a material effect on financial statements.
Received a final audit report and assessments from the German Federal Central Tax Office (FCTO) for tax years 2010 through 2017 totaling $754 million, with an additional $11 million expected; the company intends to defend its filing positions.
The European Representative Actions Directive (Collective Redress Directive) and the revised European Product Liability Directive (effective December 9, 2026) expose the company to additional litigation risks and potential significant legal expenses.

Stakeholder Impact

Shareholders: Benefit from increased dividends ($3.400 per share in 2025) and potential share repurchases ($1,033 million authorized remaining). However, potential dilution from preferred stock issuance and impact of anti-takeover provisions could affect control.
Employees: Benefit from competitive pay and benefits, extensive development programs, and share-based compensation (stock options, RSUs, PSUs). The company's focus on an engaging culture and health/safety aims to improve employee satisfaction and retention.
Customers: Benefit from continuous product innovation and expanded offerings in MedSurg, Neurotechnology, and Orthopaedics, including advanced robotic systems and minimally invasive solutions. However, pricing pressures and potential supply chain disruptions could impact product availability and costs.
Suppliers: Participate in a supplier financing program, enabling earlier payment for receivables. However, supply chain risks and inflationary pressures could affect their operations and costs.
Creditors: The company's debt issuances and revolving credit facilities provide financing, but the structural subordination of notes to subsidiary liabilities and increased interest expense impact their risk and return profiles.

Next Steps

Full commercial launch of Mako Shoulder in the United States is planned for the first quarter of 2026.
Continue to monitor and evaluate the impact of new tariffs and trade policies on product costs and supply chains.
Continue to evaluate the impact of tax reform in various countries, including new guidance and regulations related to OECD Pillar 1 and Pillar 2 frameworks.
Defend filing positions through the German Federal Central Tax Office (FCTO) independent appeals process and/or litigation regarding tax assessments for 2010-2017.
Comply with the European Product Liability Directive, which will be fully adopted into national laws by December 9, 2026.

Key Dates

Date	Description
January 15, 2010	Base indenture date for several debt notes.
March 25, 2013	Fifth Supplemental Indenture (2043 notes).
May 1, 2014	Seventh Supplemental Indenture (2044 notes).
November 3, 2014	Settlement Agreement for Rejuvenate and ABF II Hip Implant Products Liability Litigation.
October 29, 2015	Eighth Supplemental Indenture (2025 notes).
March 10, 2016	Eleventh Supplemental Indenture (2026 note) and Twelfth Supplemental Indenture (2046 note).
May 2017	European Union Medical Device Regulation enacted.
March 7, 2018	Fourteenth Supplemental Indenture (2028 note).
November 30, 2018	Sixteenth Supplemental Indenture (2027 note) and Seventeenth Supplemental Indenture (2030 note).
November 30, 2019	Beginning of annual interest payment for 2027 and 2030 notes.
December 3, 2019	Twentieth Supplemental Indenture (2029 note) and Twenty-First Supplemental Indenture (2031 note).
June 4, 2020	Twenty-Second Supplemental Indenture (2025 note), Twenty-Third Supplemental Indenture (2030 note), Twenty-Fourth Supplemental Indenture (2050 note).
December 3, 2020	Beginning of annual interest payment for 2031 notes.
March 1, 2021	Beginning of annual interest payment for 2029 notes.
October 2021	Date of previous revolving credit agreement.
January 6, 2022	Agreement and Plan of Merger with Vocera Communications, Inc.
May 2022	Original effective date of EU Medical Device Regulation.
2023	Extended transition timelines for EU Medical Device Regulation published, ranging from May 2026 through December 2028.
December 8, 2023	Twenty-Sixth Supplemental Indenture (2028 note).
December 11, 2023	Twenty-Seventh Supplemental Indenture (2028 note). Beginning of annual interest payment for 3.375% Notes due 2028.
April 30, 2024	Company obtained a tax ruling from the Israeli Tax Authority (ITA) regarding the tax treatment of Restricted Stock Units (RSUs).
September 11, 2024	Twenty-Eighth Supplemental Indenture (2032 note), Twenty-Ninth Supplemental Indenture (2036 note), Thirtieth Supplemental Indenture (2029 note), Thirty-First Supplemental Indenture (2034 note). Beginning of annual interest payment for 3.375% Notes due 2032 and 3.625% Notes due 2036.
November 2024	Management committed to a plan to sell certain assets associated with the Spinal Implants business, classifying them as held for sale.
November 2024	Information reflected in Addendum for stock options/RSUs/PSUs.
December 11, 2024	Beginning of annual interest payment for 3.375% Notes due 2028.
January 1, 2025	Adoption of ASU 2023-09 (Topic 740): Income Taxes: Improvements to Income Tax Disclosures.
January 6, 2025	Agreement and Plan of Merger with Inari Medical, Inc.
January 27, 2025	Letter Agreement between Stryker Corporation and Preston Wells.
February 2025	Acquisition of Inari Medical, Inc. completed. New revolving credit agreement entered. Issued $500M 4.550% notes due 2027, $700M 4.700% notes due 2028, $800M 4.850% notes due 2030, $1,000M 5.200% notes due 2035.
February 10, 2025	Thirty-Second Supplemental Indenture (2027 note), Thirty-Third Supplemental Indenture (2028 note), Thirty-Fourth Supplemental Indenture (2030 note), Thirty-Fifth Supplemental Indenture (2035 note).
February 25, 2025	Maturity date extended for revolving credit agreement.
March 2025	Full market release of Mako Total Hip with Advanced Primary and Revision application (Q3 2025).
April 1, 2025	DOJ closed its FCPA inquiry.
April 2025	Sale of Spinal Implants business completed.
May 8, 2025	2011 Long-Term Incentive Plan amended and restated.
May 2025	Ms. King joined Stryker as Vice President, Chief Digital and Information Officer.
June 2025	Repaid $650 million of 1.150% senior unsecured notes.
June 30, 2025	Aggregate market value of voting stock held by non-affiliates was approximately $144,306,436,547.
July 2025	FASB issued ASU 2025-05 (Topic 326): Financial Instruments Credit Losses: Measurement of Credit Losses for Accounts Receivable and Contract Assets.
November 2025	Repaid $750 million of 3.375% senior unsecured notes.
December 2025	FASB issued ASU 2025-10 (Topic 832): Accounting for Government Grants Received by Business Entities.
December 16, 2025	SEC closed its FCPA inquiry.
December 31, 2025	Fiscal year end for the annual report.
January 31, 2026	Number of common stock shares outstanding was 382,688,675.
February 4, 2026	Grant date for 2026 stock options, RSUs, and PSUs.
February 11, 2026	Date of the audit report and filing of the 10-K.
March 3, 2026	Start of acceptance window for 2026 stock options, RSUs, and PSUs.
March 31, 2026	End of acceptance window for 2026 stock options, RSUs, and PSUs. Deadline for signing Non-Compete Agreement for vesting of awards.
April 30, 2026	Deadline for returning Addendum for stock options, RSUs, and PSUs via email.
May 2026	Earliest extended transition timeline for complying with European Union Medical Device Regulation.
December 9, 2026	European Product Liability Directive will become fully adopted into each member state's national laws.
December 15, 2026	Effective date for ASU 2024-03 (Income Statement: Reporting Comprehensive Income Expense Disaggregation Disclosures).
February 10, 2027	Maturity date for 4.550% senior unsecured notes issued in February 2025.
March 21, 2027	First vesting date for 2026 Restricted Stock Units (RSUs).
August 31, 2027	Optional redemption date for 2.125% Notes due 2027.
November 30, 2027	Maturity date for 2.125% Notes due 2027.
December 15, 2027	Effective date for ASU 2025-06 (Intangibles Goodwill and Other Internal-Use Software: Targeted Improvements to the Accounting for Internal-Use Software).
February 10, 2028	Maturity date for 4.700% senior unsecured notes issued in February 2025.
September 11, 2028	Par Call Date for 3.375% Notes due 2028.
December 1, 2028	Optional redemption date for 0.750% Notes due 2029.
December 15, 2028	Latest extended transition timeline for complying with European Union Medical Device Regulation. Effective date for ASU 2025-10 (Accounting for Government Grants Received by Business Entities).
December 31, 2028	End of Performance Period for 2026 Performance Stock Units (PSUs).
March 21, 2029	Vesting date for 2026 Performance Stock Units (PSUs).
December 31, 2029	Latest date for issuing shares for vested EPS PSUs and Sales Growth PSUs.
February 10, 2030	Maturity date for 4.850% senior unsecured notes issued in February 2025.
February 25, 2030	Maturity date for the new revolving credit agreement.
August 31, 2030	Optional redemption date for 2.625% Notes due 2030.
November 30, 2030	Maturity date for 2.625% Notes due 2030.
September 3, 2031	Optional redemption date for 1.000% Notes due 2031.
December 3, 2031	Maturity date for 1.000% Notes due 2031.
June 11, 2032	Par Call Date for 3.375% Notes due 2032.
September 11, 2032	Maturity date for 3.375% Notes due 2032.
February 10, 2035	Maturity date for 5.200% senior unsecured notes issued in February 2025.
February 3, 2036	Expiration date for 2026 stock options.
June 11, 2036	Par Call Date for 3.625% Notes due 2036.
September 11, 2036	Maturity date for 3.625% Notes due 2036.

Recommendation

hold

Stryker's 2025 performance demonstrates strong operational execution and strategic growth through acquisitions and product innovation, justifying a 'hold' recommendation. While the company exhibits robust sales and adjusted earnings growth, the significant increase in interest expense and effective tax rate, coupled with ongoing legal and regulatory challenges (e.g., German tax audit, EU product liability changes), introduce elements of uncertainty. The ERP system implementation and cybersecurity risks also warrant careful monitoring. Seasoned investors would likely maintain their positions, awaiting further clarity on these headwinds while appreciating the company's strong market position and consistent innovation.

Keywords

Medical Technology, Orthopaedics, Neurotechnology, MedSurg, SEC Filing, 10-K, Financial Performance, Acquisitions, Product Launches, Mako SmartRobotics, Surgical Equipment, Implants, Risk Factors, Corporate Governance, Debt Securities, Cybersecurity, Taxation, Supply Chain, Healthcare Industry, Stryker

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.